Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Regeneron Pharmaceutical (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 39,917,184
  • Shares Outstanding, K 107,440
  • Annual Sales, $ 4,860 M
  • Annual Income, $ 895,520 K
  • 36-Month Beta 1.53
  • Price/Sales 7.81
  • Price/Cash Flow 36.96
  • Price/Book 6.59

Price Performance

See More
Period Period Low Period High Performance
1-Month
363.00 +2.95%
on 01/11/18
396.78 -5.82%
on 01/03/18
-7.30 (-1.92%)
since 12/22/17
3-Month
353.14 +5.82%
on 11/29/17
437.90 -14.66%
on 10/23/17
-59.28 (-13.69%)
since 10/20/17
52-Week
340.09 +9.88%
on 01/26/17
543.55 -31.25%
on 06/22/17
+11.14 (+3.07%)
since 01/20/17

Most Recent Stories

More News
Regeneron Announces Approval of DUPIXENT® (dupilumab) in Japan for the Treatment of Atopic Dermatitis

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for DUPIXENT® (dupilumab)...

REGN : 373.59 (+0.55%)
Ophthotech Begins Phase II Zimura Study in Stargardt Disease

Ophthotech (OPHT) is focusing on Zimura following the failure of the Fovista studies.

VYGR : 19.93 (+6.75%)
OPHT : 3.03 (+3.06%)
RHHBY : 30.7500 (+0.20%)
REGN : 373.59 (+0.55%)
Regeneron Pharm Set to Possibly Pullback After Yesterday's Rally of 1.63%

Regeneron Pharm (NASDAQ:REGN) traded in a range yesterday that spanned from a low of $367.35 to a high of $374.81. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high...

REGN : 373.59 (+0.55%)
Can Biotech Keep Last Year's Momentum Alive in 2018?

The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

CELG : 102.88 (+0.22%)
VRTX : 160.73 (+1.75%)
EXEL : 28.98 (+3.50%)
GILD : 81.29 (+0.38%)
REGN : 373.59 (+0.55%)
AMGN : 192.32 (+1.61%)
ALXN : 123.11 (+1.70%)
Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.

CELG : 102.88 (+0.22%)
VRTX : 160.73 (+1.75%)
AXON : 2.15 (+5.91%)
ABBV : 106.18 (+1.47%)
GILD : 81.29 (+0.38%)
ACOR : 27.20 (+0.37%)
REGN : 373.59 (+0.55%)
AbbVie's Upadacitinib Gains Breakthrough Therapy Designation

AbbVie's (ABBV) atopic dermatitis (eczema) candidate, upadacitinib, gets breakthrough therapy status from the FDA.

CLDX : 2.79 (+1.09%)
ABBV : 106.18 (+1.47%)
REGN : 373.59 (+0.55%)
SNY : 43.17 (-3.21%)
Regeneron, Sanofi Expand Investment in Cemiplimab & Dupilumab

Regeneron (REGN) and partner Sanofi announced that they will expand their investment for the development cemiplimab in oncology, and label expansion of dupilumab in Type II allergic diseases.

ALNY : 130.19 (+4.29%)
REGN : 373.59 (+0.55%)
PFE : 36.89 (-0.14%)
SNY : 43.17 (-3.21%)
Stock Market News For Jan 9, 2018

Markets finished mostly higher on Monday even as safe haven stocks such as utilities and real estate gained traction

NFLX : 225.43 (+2.25%)
GOOGL : 1,164.15 (+1.81%)
LULU : 79.04 (-0.38%)
NVDA : 232.81 (+1.17%)
JPM : 113.36 (+0.31%)
BGFV : 6.10 (unch)
KSS : 67.39 (-0.22%)
FB : 184.13 (+1.57%)
GS : 260.87 (+1.85%)
REGN : 373.59 (+0.55%)
AMZN : 1,315.55 (+1.62%)
BIIB : 344.04 (+0.48%)
FDA Approvals Surge in 2017: Here's a Look at the Numbers

There was a significant surge in FDA approvals in 2017 with the regulatory body giving its nod to 46 novel drugs plus gene-based therapies like Novartis's (NVS) Kymriah. Here is a closer look at the numbers...

LLY : 85.27 (-0.26%)
GWPH : 133.87 (+1.10%)
NVS : 86.72 (-0.25%)
GILD : 81.29 (+0.38%)
RHHBY : 30.7500 (+0.20%)
REGN : 373.59 (+0.55%)
AMGN : 192.32 (+1.61%)
Momenta Reports Positive Top-Line Data on Antibody M281

Momenta reported positive top-line results from a phase I study on M281 wherein the candidate did not show any adverse event, was well tolerated, and decreased circulating IgG levels up to 89%.

MYL : 47.19 (+0.98%)
MNTA : 16.10 (-1.83%)
TEVA : 20.96 (+1.26%)
REGN : 373.59 (+0.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Regeneron is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma and has preclinical...

See More

Key Turning Points

2nd Resistance Point 378.50
1st Resistance Point 375.01
Last Price 373.59
1st Support Level 369.50
2nd Support Level 367.48

See More

52-Week High 543.55
Fibonacci 61.8% 465.83
Fibonacci 50% 441.82
Fibonacci 38.2% 417.81
Last Price 373.59
52-Week Low 340.09

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.